Opportunities in MRD detection and intervention in multiple solid tumors

Scott Kopetz, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, highlights methodologies to improve patient outcomes through minimal residual disease (MRD) detection. Examples include the use of precise assays to detect smaller amounts of disease in patients with melanoma, as well as in those with pancreatic and colorectal cancers. Such techniques can also help detect MRD after surgical resection and allow more patients to benefit from more directed, novel therapies including immunotherapies. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.